The safety and efficacy of Australian tick-borne disease vaccine strains in cattle in Paraguay

Brizuela, C.M.; Ortellado, Carlos; Sanabria, Edgar; Torres, O; Ortigosa, D

doi:10.1016/s0304-4017(97)00047-2

Cited by 20 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An infection exclusion phenomenon was demonstrated in another study in which cattle simultaneously inoculated with two A. marginale isolates became infected with only one isolate, apparently excluding the other (48). The same phenomenon was demonstrated in an Anaplasma-tick cell culture system (48) and naturally infected ticks (43 (31,69,173), and the vaccine strain has been reported to cause severe anaplasmosis in splenectomized and adult cattle (86,130). High-performance milking cows appear to be most severely affected after A. centrale infection (129), and the vaccine has been most successfully used in young cattle (130).…”

Section: Live Vaccinesmentioning

confidence: 60%

Antigens and Alternatives for Control ofAnaplasma marginaleInfection in Cattle

et al. 2003

View full text Add to dashboard Cite

Anaplasmosis, a tick-borne cattle disease caused by the rickettsia Anaplasma marginale, is endemic in tropical and subtropical areas of the world. The disease causes considerable economic loss to both the dairy and beef industries worldwide. Analyses of 16S rRNA, groESL, and surface proteins have resulted in the recent reclassification of the order Rickettsiales. The genus Anaplasma, of which A. marginale is the type species, now also includes A. bovis, A. platys, and A. phagocytophilum, which were previously known as Ehrlichia bovis, E. platys, and the E. phagocytophila group (which causes human granulocytic ehrlichiosis), respectively. Live and killed vaccines have been used for control of anaplasmosis, and both types of vaccines have advantages and disadvantages. These vaccines have been effective in preventing clinical anaplasmosis in cattle but have not blocked A. marginale infection. Thus, persistently infected cattle serve as a reservoir of infective blood for both mechanical transmission and infection of ticks. Advances in biochemical, immunologic, and molecular technologies during the last decade have been applied to research of A. marginale and related organisms. The recent development of a cell culture system for A. marginale provides a potential source of antigen for the development of improved killed and live vaccines, and the availability of cell culture-derived antigen would eliminate the use of cattle in vaccine production. Increased knowledge of A. marginale antigen repertoires and an improved understanding of bovine cellular and humoral immune responses to A. marginale, combined with the new technologies, should contribute to the development of more effective vaccines for control and prevention of anaplasmosis

show abstract

Section: Live Vaccinesmentioning

confidence: 60%

Antigens and Alternatives for Control ofAnaplasma marginaleInfection in Cattle

et al. 2003

View full text Add to dashboard Cite

show abstract

“…The increase in legislation to combat the detrimental effect of residues of acaricides on the environment, have emphasized the need to assess a variety of alternatives to tick vector control. There is an Australian tick vaccine already on the market, Bm 86 vaccine TickGARD (PLUS) against infestations with the cattle tick B. microplus [13,20,33]. There is evidence for a strong cross protection with B. decolaratus, H. anatolicum and Hyalomma dromedarri, but with little effect on R. appendiculatus or Amblyoma variegatum.…”

Section: Vector Controlmentioning

confidence: 99%

“…The latter is restricted to some commercial farms, but it is not common practice. The reported success of immunization using tick fever vaccines in Australia [12], Paraguay [13] and South Africa [21] represents a potential for the control of babesiosis and Anaplasmosis in Zambia. In these countries, Babesia strains have been shown to provide good protection against field challenge and were safe to use in highly susceptible cattle.…”

Section: Babesiosis and Anaplasmosismentioning

confidence: 99%

The current status of major tick borne diseases in Zambia

Makala

Mangani²,

Fujisaki

et al. 2003

Vet. Res.

View full text Add to dashboard Cite

-Tick-borne diseases occurring in Zambia are assuming more importance as they continue to be a major economic problem not only in Zambia, but in many parts of Eastern, Southern and Central Africa. The current control methods, which include the use of toxic acaricides to kill ticks, and the virulent sporozoite infection and treatment method have limitations. Recombinant vaccines, currently in their experimental stages, offer hope for the future. The use of acaricides is hampered by the development of acaricide resistance and live vaccines are dependent on cold chain facilities, which are a formidable obstacle in the poorly developed infrastructure in parts of Zambia where the vaccine is most needed. Amidst these drawbacks are the results of the recent research on parasites and vector recombinant vaccines which promise to circumvent these problems. The history, current status and attitudes regarding the control of these diseases, taking into account their complexity, are reviewed. The establishment of the well-designed Central Veterinary Research Institute (CVRI) and Japanese International Cooperation Agency (JICA) sponsored veterinary school, both have a potential for high quality research, with access to a wealth of specimens a veritable goldmine of research material. It is thus hoped that this review will stimulate the desire to maximize the value of the tick and tick-borne disease research in both Zambia and the international research community.

show abstract

“…Additionally, immunity induced by live vaccination with A. marginale subsp. centrale is not uniform against all strains and outbreaks have been reported in immunized populations (Brizuela et al, 1998;Turton et al, 1998). However, the overall efficacy of this vaccine demonstrates that protection against heterologous challenge in terms of disease prevention is possible (Shkap et al, 2002).…”

Section: Identification Of a Marginale Vaccine Targetsmentioning

confidence: 96%